Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
复制标题
DOI：
10.1038/leu.2013.217
复制
发表时间：
2014-02-01
期刊：
影响因子：
11.4
通讯作者：
Garcia-Sanz, R.
中科院分区：
文献类型：
--
作者：
Puig, N.;Sarasquete, M. E.;Garcia-Sanz, R.
我们分析了等位基因特异性寡核苷酸实时定量PCR（阿索RQ-PCR）作为多发性骨髓瘤（MM）患者微小残留病（MRD）评估方法的适用性、敏感性和预后价值，并与多参数流式细胞术（MFC）的结果进行比较。共纳入170例连续三项西班牙试验的患者，治疗后至少达到部分缓解。缺乏克隆性检测（n = 31）、测序不成功（n = 17）和阿索性能欠佳（n = 51）限制了PCR对42%病例的适用性。最终在103例（包括32例先前研究的患者）中研究了MRD，其中PCR和MFC分别在54%和46%的病例中确定了持续性疾病。两种方法的MRD定量结果具有显著相关性（r = 0.881，P
We have analyzed the applicability, sensitivity and prognostic value of allele-specific oligonucleotide real-time quantitative PCR (ASO RQ-PCR) as a method for minimal residual disease (MRD) assessment in patients with multiple myeloma (MM), comparing the results with those of multiparameter flow cytometry (MFC). A total of 170 patients enrolled in three consecutive Spanish trials achieving at least partial response after treatment were included. Lack of clonality detection (n = 31), unsuccessful sequencing (n = 17) and suboptimal ASO performance (n = 51) limited the applicability of PCR to 42% of cases. MRD was finally investigated in 103 patients (including 32 previously studied) with persistent disease identified by PCR and MFC in 54% and 46% of cases, respectively. A significant correlation in MRD quantitation by both the techniques was noted (r = 0.881, P